310 related articles for article (PubMed ID: 10636535)
1. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
[TBL] [Abstract][Full Text] [Related]
2. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F;
Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
7. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
Zhao XQ; Théroux P; Snapinn SM; Sax FL
Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
[TBL] [Abstract][Full Text] [Related]
8. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
9. The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Cohen M; Maritz F; Gensini GF; Danchin N; Timerman A; Huber K; Gurfinkel EP; White H; Fox KA; Vittori L; Le-Louer V; Bigonzi F
J Thromb Thrombolysis; 2000 Dec; 10(3):241-6. PubMed ID: 11122544
[TBL] [Abstract][Full Text] [Related]
10. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Okmen E; Cakmak M; Tartan Z; Cam N
Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
[TBL] [Abstract][Full Text] [Related]
11. Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor.
Okmen E; Ozen E; Uyarel H; Sanli A; Tartan Z; Cam N
Jpn Heart J; 2003 Nov; 44(6):899-906. PubMed ID: 14711185
[TBL] [Abstract][Full Text] [Related]
12. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL
Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818
[TBL] [Abstract][Full Text] [Related]
14. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA
Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632
[TBL] [Abstract][Full Text] [Related]
15. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
[TBL] [Abstract][Full Text] [Related]
16. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?
White HD
J Invasive Cardiol; 2000 Feb; 12 Suppl A():6A-13A. PubMed ID: 10731290
[TBL] [Abstract][Full Text] [Related]
18. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes.
Januzzi JL; Hahn SS; Chae CU; Giugliano R; Lewandrowski K; Theroux P; Jang IK
Am J Cardiol; 2000 Oct; 86(7):713-7. PubMed ID: 11018188
[TBL] [Abstract][Full Text] [Related]
19. Optimizing outcomes in ST-segment elevation myocardial infarction.
Herrmann HC
J Am Coll Cardiol; 2003 Oct; 42(8):1357-9. PubMed ID: 14563574
[No Abstract] [Full Text] [Related]
20. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
